Seegene
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Seegene makes diagnostic reagents, chemical test kits used in laboratories to identify the genetic material of disease-causing pathogens from patient samples, a field known as molecular diagnostics.
Its products are supplied to hospitals and testing institutions worldwide, distributed through local subsidiaries and a network of agents spanning over a hundred countries. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company earns the vast majority of its revenue from exports, with overseas sales accounting for nearly all of its total revenue. Its core technology allows a single test tube to simultaneously detect multiple pathogens, and it holds dozens of proprietary patents covering this approach.
Summary is AI-generated and may contain errors · figures from DART filings
Seegene has entered a technology-sharing initiative, including a strategic collaboration with Microsoft to apply artificial intelligence to its reagent-development automation platform.
Seegene in five facts
What does Seegene do?
Seegene makes diagnostic reagents, chemical test kits used in laboratories to identify the genetic material of disease-causing pathogens from patient samples, a field known as molecular diagnostics.
Where is Seegene listed and in which sector?
Seegene (Korean name: 씨젠) trades under KRX code 096530 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Seegene?
Its market capitalisation was US$1.3B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Seegene's latest annual revenue and operating profit?
For fiscal year 2025, Seegene reported revenue of US$357.9M, operating profit of US$26.1M and net income of US$36.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 14.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Executives/major shareholders' securities trading planOct 21
- Executives/major shareholders' securities trading planOct 19
- DisclosureSep 28
- Treasury share disposal: results report
Seegene reports disposal of 183 treasury common shares on 2026-08-13 at a per-share book price (moving-average cost) of US$22.75, for total proceeds of US$4.16K, via internal account transfer.
Treasury Shares · Aug 21 - Cash/in-kind dividend decision (quarterly dividend)
Seegene declared a cash dividend of US$0.21 per share, equal to about 1.1% of the recent share price.
Dividend · Aug 12 - Material event report (treasury share disposal)
Seegene disclosed a plan to sell treasury shares worth US$4.21K, about 0.0% of its market value.
Treasury Shares · Aug 12 - Operating results (consolidated) (preliminary) (fair disclosure)
Seegene filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$95.6M (+19.2% year on year), operating profit of US$15.2M (+586.4% year on year) and net income of US$18.2M (from a loss a year earlier).
Earnings · Aug 7 - Treasury share disposal: results reportTreasury Shares · May 21
- Operating results (consolidated) (preliminary) (fair disclosure)
Seegene filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$88.8M (+11.3% year on year), operating profit of US$16.2M (+58.6% year on year) and net income of US$23.9M (+20.1% year on year).
Earnings · May 8 - Cash/in-kind dividend decision
Seegene declared a cash dividend of US$0.21 per share, equal to about 1.3% of the recent share price.
Dividend · May 6 - Material event report (treasury share disposal)
Seegene disclosed a plan to sell treasury shares worth US$14.7K, about 0.0% of its market value.
Treasury Shares · May 6 - Treasury share disposal: results reportTreasury Shares · May 6
- Material event report (treasury share disposal)
Seegene disclosed a plan to sell treasury shares worth US$122K, about 0.0% of its market value.
Treasury Shares · Apr 10 - Treasury share disposal: results reportTreasury Shares · Apr 10
- Cash/in-kind dividend decision
Seegene declared a cash dividend of US$0.27 per share, equal to about 1.6% of the recent share price.
Dividend · Mar 11 - Material event report (treasury share disposal)
Seegene disclosed a plan to sell treasury shares worth US$41.7K, about 0.0% of its market value.
Treasury Shares · Mar 11 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Seegene reported consolidated results for FY2025: revenue of US$329M (+14.5% year on year), operating profit of US$24M (from a loss a year earlier) and net income of US$33.6M (from a loss a year earlier).
Earnings · Feb 25 - Operating results (consolidated) (preliminary) (fair disclosure)
Seegene filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$90.7M (+13.3% year on year), operating profit of US$4.83M (from a loss a year earlier) and net income of US$11.5M (from a loss a year earlier).
Earnings · Feb 25